The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 28, 2021

Filed:

Apr. 11, 2019
Applicant:

The Trustees of Princeton University, Princeton, NJ (US);

Inventors:

Thomas Shenk, Princeton, NJ (US);

Dai Wang, Blue Bell, PA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/245 (2006.01); A61K 39/12 (2006.01); C07K 14/005 (2006.01); C07K 16/08 (2006.01); C12N 7/00 (2006.01); C12Q 1/02 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/245 (2013.01); A61K 39/12 (2013.01); C07K 14/005 (2013.01); C07K 16/085 (2013.01); C07K 16/088 (2013.01); C12N 7/00 (2013.01); C12Q 1/025 (2013.01); A61K 2039/505 (2013.01); C07K 2317/76 (2013.01); C12N 2710/16122 (2013.01); C12N 2710/16134 (2013.01); G01N 2500/04 (2013.01);
Abstract

Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.


Find Patent Forward Citations

Loading…